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Abstract
Recent efforts in the area of acoustic droplet vaporization with the objective of designing
extravascular ultrasound contrast agents has led to the development of stabilized, lipid-
encapsulated nanodroplets of the highly volatile compound decafluorobutane (DFB). We have
developed two methods of generating DFB droplets, the first of which involves condensing DFB
gas (boiling point of −1.1° to −2° C) followed by extrusion with a lipid formulation in HEPES
buffer. Acoustic droplet vaporization of micron-sized lipid-coated droplets at diagnostic
ultrasound frequencies and mechanical indices were confirmed optically. In our second
formulation methodology, we demonstrate the formulation of sub-micron sized lipid-coated
nanodroplets based upon condensation of pre-formed microbubbles containing DFB. The droplets
are routinely in the 200 – 300 nm range and yield microbubbles on the order of 1 – 5 microns once
vaporized, consistent with ideal gas law expansion predictions. The simple and effective nature of
this methodology allows for the development of a variety of different formulations that can be
used for imaging, drug and gene delivery, and therapy. This study is the first to our knowledge to
demonstrate both a method of generating ADV agents by microbubble condensation and
formulation of primarily sub-micron droplets of decafluorobutane that remain stable at
physiological temperatures. Finally, activation of DFB nanodroplets is demonstrated using
pressures within the FDA guidelines for diagnostic imaging, which may minimize the potential for
bioeffects in humans. This methodology offers a new means of developing extravascular contrast
agents for diagnostic and therapeutic applications.
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Introduction
Microbubbles for diagnostic ultrasound imaging have been established in the clinical arena
as a sensitive and inexpensive imaging technique for interrogating landmarks in the
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vasculature. Currently, microbubble-enhanced diagnostic ultrasound has been approved by
the FDA for the study of wall motion abnormalities and ventricular contraction in
echocardiography.1 Researchers have proposed microbubble-aided ultrasound for a wide
range of potential applications, including functional tumor, kidney, and liver imaging,
identification of vascular inflammation and vulnerable plaque deposition, thrombus
detection, and targeted molecular imaging of angiogenesis.2–6 In addition to the
aforementioned studies, microbubbles have been used for therapeutic interventions;
primarily in concert with ultrasound-mediated cavitation for sonothrombolysis.
Despite their utility as vascular contrast agents and potential for therapeutic applications,
microbubble size (typically 1 – 5 microns in diameter) prevents their transport outside of the
vasculature - commonly referred to as extravasation. The exact size limit for nanoparticle
extravasation into the interstitial space in solid tumors depends on a variety of factors, but
usually falls within the range of 100 nm – 750 nm.7 Bubbles small enough to diffuse past
these inter-endothelial gap junctions would scatter ultrasound energy poorly compared to
typical microbubbles, and would provide limited imaging contrast.8 Additionally,
microbubble circulation in vivo is shown to be on the order of tens of minutes before bubble
dissolution and clearance significantly limits contrast enhancement.9,10 This short time
period may be insufficient for enough bubbles to accumulate by diffusion into the tumor
interstitium.
Recently there has been interest in the concept of ultrasound-mediated vaporization of
perfluorocarbon (PFC) droplets for the purposes of vascular occlusion, ultrasound-mediated
tissue ablation, and contrast enhancement of the tumor interstitium combined with drug
delivery.11–14 The phenomenon by which droplets undergo a phase-shift as a result of
acoustic pressure is most commonly noted in the literature as acoustic droplet vaporization
(ADV).15,16 Many in vitro studies have shown that the acoustic output necessary to induce
vaporization increases as a function of decreased diameter, decreased frequency, and
increased perfluorocarbon boiling point.13,17,18 While preliminary in vivo studies have been
promising11,14,19, applications involving relatively low frequencies and/or sub-micron
droplets may require pressures higher than diagnostic ultrasound machines currently
provide12, increasing the potential for unwanted bioeffects. Thus, a nanometer-scale droplet
or nanodroplet that is more susceptible to ultrasound pressures yet stable at physiological
temperatures could provide a more efficacious vehicle for extravasation into tissue and
activation at the site of action in many applications. The main objective of this study was to
develop stable sub-micron droplets capable of being vaporized using frequencies and
mechanical indices within the FDA-approved limits of commercial clinical diagnostic
ultrasound machines.
Work by others involving nanodroplets capable of diffusing past the vascular endothelial
membrane in solid tumors for the purpose of ADV or as liquid ultrasound scatterers have
typically utilized perfluorocarbons with boiling points above room temperature (25° C), and
have relied on extrusion or emulsification to generate droplets.12,14,20–22 Initial studies in
the laboratory of Rapoport and coworkers14 used the Antoine vapor pressure equation23 to
assess the theoretical vaporization temperature dependence upon droplet diameter of
selected perfluorocarbons as a result of the influence of interfacial surface tension. They
concluded that the temperatures required to vaporize smaller droplets increased
geometrically as droplet size decreased into the submicron range. Extending this model to
investigate the influence of perfluorocarbon boiling points reveals that less volatile PFC
compounds such as dodecafluoropentane, perfluorohexane, perfluoroheptane, etc., may
require a relatively large amount of energy in order to elicit droplet vaporization at a size
that would practically be able to extravasate through endothelial gap junctions into the
extravascular space (see Figure 1). Assuming a correlation between the temperature increase
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over body temperature needed to vaporize and ultrasound energies, the lower boiling PFCs,
such as decafluorobutane (DFB) and octafluoropropane, may be more attractive for certain
applications since the acoustic energy required to induce ADV would be significantly less.
This issue becomes especially important when designing an agent for extravascular
diagnostic ultrasound imaging, as high acoustic energies may result in unwanted bioeffects.
However, the utilization of perfluorobutane (boiling point of −1.1° to −2° C)26 and other
compounds with boiling points far below physiological and room temperatures can make
stabilized droplet formulation somewhat challenging. Nonetheless, should these PFCs be
successfully condensed and stabilized, their utility as ultrasound-mediated bubble precursors
for extravascular applications would expand the possibilities of diagnostic ultrasound
imaging and drug delivery. Recent efforts in our laboratories have indicated that this indeed
may be the case.27
An ideal extravascular ultrasound contrast agent for applications where thermal and
cavitation-based bioeffects are minimized should be: 1) stable in the vasculature for a
sufficient time period: 2) capable of extravasation out of the vascular space, and: 3) labile
enough to be activated and interrogated by clinical ultrasound machines at clinically relevant
acoustic intensities. This manuscript details our recent work to develop decafluorobutane
nanodroplets with the aforementioned characteristics in mind.
We report two methods to formulate decafluorobutane nanodroplets. The first methodology
involves condensing and extruding a lipid and DFB formulation at a temperature below the
boiling point of DFB, as reported previously.27 The second methodology involves a simple
process of first generating lipid-coated microbubbles through standard agitation-based
techniques28 followed by ambient air pressurization and slow cooling to condense the gas
core of the microbubbles, resulting in sub-micron liquid droplets. The latter methodology
offers the advantage of making smaller, more uniform droplet sizes with peaks on the order
of 200 – 300 nm - small enough for potential extravasation into solid tumors. Vaporization
of the droplets generated from both techniques is performed at acoustic energy parameters
compatible with clinical diagnostic ultrasound machines. In this latter method, which we
refer to as ‘nanodroplet generation via microbubble condensation’, we have developed a
simple, resource-efficient method to create droplets predominantly in the sub-micron range
consisting of DFB in an encapsulating shell. When exposed in vitro to a 2 µs ultrasound
pulse at 5 MHz and MI = 1.2, the generated nanodroplets yield a distribution of
microbubbles that corresponds well with expected expansion of the initial droplets through
ideal gas law predictions with surface tension effects included27,29. These results indicate
the potential usefulness of decafluorobutane nanodroplets as a potential ultrasound contrast
agent for extravascular imaging.
Materials and Methods
Decafluorobutane Droplet Formulation via Extrusion
Lipid thin films were prepared with a composition containing 85 mole percent
dipalmitoylphosphatidylcholine (DPPC), 10 mole percent 1-palmitoyl-2-hydroxy-sn-
glycero-3-phosphocholine (LPC), and 5 mole percent 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG- 2000) (Avanti
Polar Lipids, Alabaster, Ala). The lipids were first dissolved in chloroform (EMD
Chemicals, Brookfield, WI) and dried over nitrogen gas, then further dried in vacuo
overnight to remove residual solvent from the lipid films. Approximately 1 mL of HEPES
(4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) buffer (pH = 7.4) was used to
rehydrate the films, which were then sonicated for 10 minutes in a water bath sonicator
(Branson 1510, Danbury, CT) at 50 – 60° C. The rehydrated films were subjected to 10
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freeze-thaw cycles using an isopropanol bath with dry ice and thawing with a 50 – 60° C
water bath, followed by 10 minutes of stirring at 50 – 60° C. This created a lipid suspension
which was immediately stirred for 10 minutes at 50–60 °C. The resulting 20 mg/mL lipid
suspension was mixed with glycerol (20%, v:v) just prior to performing the extrusion.
Decafluorobutane (FluoroMed, Round Rock, TX) was condensed in a Secure™ EVA
Container (Metrix Co., Dubuque, IA) over dry ice. The condensed DFB was poured into a 2
mL glass vial, crimped, and stored at −20° C to preserve the liquid state. The lipid solution
(1.5 mL) was brought into the −20° C cold room and allowed to cool to approximately −2°
to −5° C, after which 200 µL of DFB was mixed with the lipid solution. The samples were
extruded by 20 passes through a 1 µm porous membrane filter (Whatman Ltd., Piscataway,
NJ) while the lipid solution was near −5° C to avoid freezing of the aqueous solution and
maintain the liquid state of the DFB. After extrusion, the resulting emulsion was stored at 4°
C in a crimped 2 mL vial with room air in the headspace. Samples were observed throughout
the extrusion process to make sure they did not freeze.
Nanodroplet Formulation via Microbubble Condensation using Room Air
Decafluorobutane microbubbles were formulated by the dissolution of 1,2-dipalmitoyl-sn-
glycero 3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphatidylethanolamine-polyethyleneglycol-2000 (DPPE-PEG-2000), and 1,2-
dipalmitoyl-3-trimethylammonium propane (chloride salt; 16:0 TAP) in a molar ratio of
65:5:30 and a total lipid concentration of 0.75 mg/mL, 1.5 mg/mL, and 3 mg/mL. The
excipient liquid was comprised of propylene glycol, glycerol, and normal saline (15:5:80).
After adding 1.5 mL of the resulting solution to a 2 mL vial, microbubbles were formed via
agitation using a Vialmix™ shaker (Bristol-Myers-Squibb, New York, NY) for 45 seconds.
The 2 mL vial containing the formed microbubbles was then immersed in a CO2/isopropanol
bath controlled to a temperature of approximately −5° C. A 25 G syringe needle containing
30 mL of room air was then inserted into the vial septum and the plunger depressed slowly
until the headspace of the vial was pressurized to between 600 – 750 kPa (approximately
85–110 psi). Lipid freezing was avoided by observing the contents of the vial as well as the
temperature of the CO2/isopropanol solution periodically. The syringe needle was removed
from the vial after pressurizing, leaving a pressure head on the solution.
Sample Sizing
Samples prepared by each method were tested in the nanometer range using a Malvern Nano
ZS (Malvern Instruments Ltd., Malvern, Worcestershire, UK) and in the micrometer range
using an Accusizer 780A (Particle Sizing Systems, Santa Barbara, CA) for distribution
statistics. For Accusizer samples, volumes were typically 3 µL for bubbles produced by
agitation and 25–50 µL for droplets. Nano ZS sample volumes of 150 – 300 µL diluted in 1
mL of HEPES buffer (pH = 7.4) were used for extruded liquid DFB droplets and 1 mL
(undiluted) for room-air microbubble-condensed nanodroplets and lipid solution controls.
The upper sizing sensitivity on the Nano ZS was 6 µm in diameter, while the lower sizing
sensitivity on the Accusizer 780A was 0.54 µm in diameter, such that an accurate
representation of the content over a wide range of sizes could be obtained.
Acoustic Vaporization of Extruded Liquid Decafluorobutane Droplets and Microbubble
Condensation Nanodroplets
Experimental Apparatus—The setup used for these experiments was identical to that
described in earlier studies.27 Briefly, an inverted microscope (Olympus IX71, Center
Valley, PA) with a water bath passively heated to 37 °C mounted on top was interfaced with
a high-speed camera (FastCam SA1.1, Photron USA, Inc., San Diego, CA) to capture
images through a 100X NA=1.0 water immersion objective. The optical resolution of the
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system was measured to be approximately 0.5 µm, although only droplets and bubbles larger
than 1 µm could be measured with reasonable accuracy. For experiments involving degassed
water, an in-line degasser was allowed to operate for 30 minutes prior to the experiment and
turned off briefly during the vaporization to minimize the vibration present in the captured
images. Baseline oxygen saturation at 37 °C was measured to be approximately 5 PPM
(Oxygen CHEMets, CHEMetrics, Inc., Calverton, VA), which dropped to 1.5 PPM or less
after 30 minutes of degassing. The droplet solution was pumped through a nearly optically
and acoustically transparent cellulose tube with a 200 µm inner diameter (Spectrum Labs,
Inc., Greensboro, NC). A 3-axis micropositioner (MMO-203, Narishige Group, East
Meadow, NY) was used to position the cellulose tube and keep the droplets/bubbles in the
field of view, while a custom-built manual injector allowed for precise administration of the
droplets into the field of view.
A spherically focused 5 MHz transducer with a focal length of 3.81 cm. (IL0506HP, Valpey
Fisher Corp., Hopkinton, MA) was used to insonify droplet samples with signals constructed
using an arbitrary waveform generator (AWG 2021, Tektronix, Inc., Beaverton, Or). A
synchronization pulse from the waveform generator was relayed to the high speed camera in
order to trigger a marker with the acoustic pulse on the digital video. The waveform from
the generator, consisting of a 10-cycle sinusoid of adjustable amplitude at 5 MHz (total
insonification time of 2 µs), was amplified approximately 60 dB using an RF amplifier
(A500, ENI, Rochester, NY) in order to excite the transducer. For optical-acoustic
alignment, the transducer focus was matched with the optical focus by a needle hydrophone
(HNA-0400, Onda Corp., Sunnyvale, CA). The transducer was calibrated at the focus over
the range of amplitudes used to determine the pressure exerted on the droplets in the field of
view.
Analysis of images—Still images and videos were captured using proprietary camera
software (PFV, Photron USA, Inc., San Diego, CA). Image analyses were performed on the
recordings using ImageJ software (NIH, Bethesda).
Vaporization Threshold of Individual Micron-sized Droplets of Extruded Liquid
Decafluorobutane—The vaporization threshold of individual PFB droplets was
determined by first venting the undiluted samples with a 20-gauge needle and then diluting
in degassed (3 PPM oxygen saturation) phosphate-buffered saline (PBS) until only 1 – 2
droplets were visible on screen at any particular time. This typically ranged from 0.1% –2%
sample in PBS (v:v) and depended on the concentration of larger droplets present in the
original sample. The droplets were held on screen with the position manipulator and
ultrasound pressure was increased in steps of approximately 0.115 MPa with 1 – 2 seconds
of rest time between e ach trigger. The pressure that induced observed vaporization was
recorded to correlate to droplet diameter with ADV acoustic properties.
For analysis, the pressure that induced vaporization was converted to Mechanical Index
(MI), defined as:
Vaporization Threshold of Decafluorobutane Microbubble Condensation
Nanodroplets—Due to the fact that droplets smaller than 1 µm were beyond the
resolution capabilities of the experimental setup, the approach to vaporize sub-micron
droplet samples differed from the individual droplet approach previously described. Samples
were left undiluted to maximize the number of droplets and resulting bubbles in the field of
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view. Oxygenation after microbubble condensation was typically on the order of 2–3 PPM.
Once injected into the in vitro setup, the sub-micron droplet samples at each lipid
concentration (0.75, 1.5, and 3.0 mg/mL) were exposed to 5 MHz ultrasound pulses 2 µs in
duration at a mechanical index of either 1.2 or 1.7. These mechanical indices were chosen
because they represent pressures at the middle-to-higher end of what is available on a
diagnostic ultrasound machine. Videos of droplet vaporization were taken at the ‘mid-plane’
of the cellulose tube to observe bubbles as they floated past the focus, and at the top of the
tube to observe the bubbles accumulating due to buoyancy. Bubbles were counted and
measured to determine any differences in size distributions and/or quantity based on lipid
concentration. The size distributions of bubbles obtained at each mechanical index were
compared to determine the impact of the pressure level on the resulting size distribution.
Results and Discussion
Acoustic Droplet Vaporization of Decafluorobutane Formulations made via Extrusion
Liquid decafluorobutane extrusions, when sized by the Malvern and Accusizer, yielded
content in both the sub-micron and micron size range. Upon exposure to ultrasonic energy,
vaporization of the largest content present in the samples – droplets larger than 1 µm, which
could be resolved optically - was achieved at clinically relevant pressures such that an
inverse relationship between initial diameter and pressure required to vaporize could be
observed (Figure 2). Even when left un-diluted and exposed to high mechanical indices,
samples produced by this method did not yield a significant amount of bubbles in the 1–5
µm range, suggesting that the sub-micron droplets were either: 1) a small portion of the total
sample: 2) unviable: 3) aggregated: 4) required higher acoustic pressures than currently used
(the highest pressure used was MI = 2.25), or: 5) a combination of these. Micron-sized
droplets were observed to be as large as 12 – 15 µm on occasion (see Figure 3),
demonstrating that lipid-encapsulated DFB has the potential to remain stable at 37°C for a
wide range of sizes relevant to medical imaging and therapeutic applications. That droplets
this large existed after extrusion through a 1 µm-pore membrane may be due to some
coalescence, but it is expected that this is primarily a result of the low perfluorocarbon
surface tension. This, taken in conjunction with the high lipid concentrations used in this
formulation and the lack of small bubbles upon acoustic energy provide evidence that the
sub-micron content most likely consists of naturally-forming vesicles rather than DFB
droplets.
The vaporization threshold for ADV agents varies widely in the literature, as there are many
influencing test factors that modulate the pressure needed (e.g. ultrasound frequency, pulse
length, duty cycle, ambient temperature).15,17,31–35 The method used in this study to
determine the threshold - by optical verification of individual droplets stationary near the
bottom of the tube - differed from the approach of most studies to date (characterizing the
mean echo amplitude returned from a bulk sample after vaporization)17,18. Additionally,
several studies have shown that the acoustic pressure field in a microcellulose tube can
differ greatly from the free-field hydrophone measurements and is a function of frequency,
making direct comparisons across studies difficult.16,35 However, a preliminary study by our
group showed that under similar test conditions and threshold definitions,
dodecafluoropentane droplets of the same size required as much as 40 – 50 % more pressure
to induce vaporization.27
Microbubble Condensation Nanodroplets: Microbubble Size Prior to Condensation
To test our hypothesis that the size of resultant nanodroplets condensed from pre-formulated
microbubbles correlates with the original microbubble populations, initial sizing was
performed on prepared microbubbles at three lipid concentrations (Figure 4). In general, the
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mode bubble size for each concentration was relatively similar, although for the 3 mg/mL
formulation a much larger percentage of bubbles measuring greater than 1.5 µm in diameter
resulted. This was not surprising as the higher lipid concentration may stabilize larger
bubbles and skew the distribution somewhat.
Sub-micron Particle Analysis of Microbubble Condensation Nanodroplets
By assuming the number of moles is preserved between the liquid state and the gaseous
state, a theoretical relationship can be developed from ideal gas laws that relates the size of
the gas microbubbles to the size of the droplets that should be produced from microbubble
condensation.27 Sizing of resultant nanodroplets by the Malvern ZS demonstrated that the
microbubble condensation method routinely produced peaks in the 200–300 nm range,
which corresponds well with ideal gas law estimates of droplet sizes produced by the
microbubble condensation method originating from bubbles in the 1– 2 µm range (as was
the case with all microbubble preparations). While sub-micron particle sizing did not allow
for information about concentration, all three lipid concentrations appeared to result in mode
droplet sizes between 200 – 300 nm. A significant amount of variation across samples was
observed with regard to the deviation from the mode size. Some samples were measured to
have content below 100 nm, while others had only content greater than 200 nm (Figure 5)
possibly reflecting some vesicle formation as lipid concentrations increased. We believe this
variability may have resulted from inconsistencies in applied pressure and temperature at the
time of condensation, but may also be partly due to formation of micelles and liposomes as a
function of lipid concentration. This variability will be reduced as further refinements to the
methodology are made.
Sizing of controls (i.e. prior to any microbubble generation) showed that the control 3 mg/
mL formulation produced a peak near 100 nm at a low count rate (Figure 6) which may be
attributed to naturally forming vesicles (as described previously). This peak was not present
in any nanodroplet samples resulting from the 3 mg/mL lipid concentration, most likely as a
result of the process of microbubble generation. Although the Malvern was not able to
produce stable, consistent sizing results for the 0.75 mg/mL and 1.5 mg/mL samples, some
content was present in the low nanometer range at lower count rates. These results suggest
that the submicron sizings most likely represent viable, DFB-filled nanodroplets.
Micrometer-range Particle Sizing of Droplets Produced via Microbubble Condensation
The Malvern Nano ZS, which had an upper sizing threshold of 6 µm, showed the majority of
the sample content to be in the nanometer range. However, to better characterize the content
present in the micrometer range, the same samples previously presented in Figure 6 were
also sized using an Accusizer 780A (Figure 7). The results showed that after microbubble
condensation, some content as large as 2–4 µm was present in the sample, and the upper size
limit seemed to increase with lipid concentration. The nature of this larger content is
discussed later. These measurements help to support the success of the condensation
method, as they show the mode particle size shifting towards the lower limit of sensitivity
from the original bubble distribution near 1 µm. The distribution peaks of Figure 7 taken in
conjunction with the sub-micron sizings of the same samples in Figure 6 suggest that the
content in the micrometer-range represents a relatively small portion of the overall sample.
We estimate that droplets larger than 600 nm typically only comprise between 1.5 – 4% of
the overall sample by count while less than 1.5% of the total sample is between 1 µm and 6
µm. The concentration measured by the particle sizer decreased by approximately 2 orders
of magnitude, presumably due to a reduction in particle size and a significant portion of the
sample condensing to sizes below the sensitivity threshold, although secondary effects
occurring during the generation (such as bubble breakage) could also be occurring.
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Acoustic Droplet Vaporization of Decafluorobutane Microbubble Condensation
Nanodroplets
Images with the focus positioned near the mid-plane of the microcellulose tube reflected
droplet conversion captured immediately after vaporization, offering a true indication of the
size distribution of microbubbles resulting from droplet vaporization as they passed through
the optical focus due to buoyancy, although the rapid bubble rise toward the top of the tube
resulted in some picture degradation (see Figure 8). Alternatively, images captured at the top
of the tube (data not shown) when the bubbles had risen and collected (typically several
seconds after the vaporization event) were useful for visualizing the ‘bulk’ group of
microbubbles in-focus and taking more accurate measurements. It was noticed that
measurements taken at the top of the tube reflected a somewhat skewed bubble size
distribution when compared to the general sizes of bubbles observed during mid-plane
videos and is likely due to the effect of larger bubbles at the apex of the tube obscuring
smaller nearby bubbles. This was confirmed in multiple instances where smaller bubbles
could be seen to be ‘orbiting’ much larger bubbles and fell out of view shortly afterward.
While the mid-plane vaporization was useful for a ‘snapshot’ shortly after vaporization, the
measurements taken at the top of the tube were more useful because the bubbles were
stationary and the optical focus could be adjusted to capture a more complete distribution.
Nonetheless, both approaches demonstrated the effect of lipid concentration on the number
of bubbles produced from droplet vaporization.
As the droplets were not within the optical resolution of the experimental apparatus, it was
necessary to measure the resulting bubbles as precisely as possible. Several studies have
demonstrated the tendency of perfluorocarbon-filled microbubbles to uptake dissolved
ambient gasses.15,27,30 To reveal the influence of dissolved gas in the resulting microbubble
population produced from vaporized nanodroplets, samples produced with a lipid
concentration of 0.75 mg/mL were exposed to a 10 cycle pulse at 5 MHz (mechanical index
of 1.7). Using the same sample throughout the test, bubbles resulting from droplet
vaporization were measured at the top of the tube first in an un-degassed water bath (N =
239) followed by a degassed water bath (N = 228). The results show that simply degassing
the water bath media reduced the maximum bubble size observed by 62% (from 32 µm to 12
µm). The mean and mode bubble sizes were also reduced by 36% and 20%, respectively.
Mid-plane observations in a degassed water bath revealed vaporization did produce a
majority of bubbles in the 1 – 3 µm range independently of lipid concentration, although the
number of bubbles produced increased dramatically when the lipid content was increased to
3 mg/mL (Figure 8). This may be because the higher lipid concentration produces better
stabilization of bubbles through the condensation process and upon vaporization.
Table 1 lists the mean, mode, and maximum bubble size (rounded to the nearest 0.5 µm)
observed for each lipid formulation at the two different pressures tested using bubbles
measured from the top of the tube (N > 150 for each pressure). The mean and mode sizes
were presumably higher than the true sample values due to reasons mentioned above.
Minimum sizes were not included due to the fact that these could not be accurately
compared across samples due to resolution limits, although in each lipid formulation the
smallest bubble measured was near the optical resolution limit. In general, mean bubble size
was similar across all samples, but mode bubble size decreased significantly as lipid
concentration increased, indicating increased efficiency in preserving nanodroplets. This
could also be observed in images of resulting bubbles, where higher lipid concentrations not
only yielded more resulting bubbles per ultrasound pulse, but a proportionately higher
distribution of small bubbles (see Figure 8).
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Using the same 5 MHz frequency, it was observed that relatively similar distributions were
observed at mechanical indices of 1.2 and 1.7, indicating the ultrasound pressure at MI = 1.2
was sufficient to induce vaporization across the same size ranges. However, a mechanical
index of 1.7 did skew the population towards a larger proportion of smaller bubbles,
implying the higher energy was more efficiently vaporizing nanodroplets (Table 1). The
histograms of bubble sizes from each sample did not generally resemble original bubble
sizing data well until the lipid concentration of 3 mg/mL was used. At 3 mg/mL, resulting
bubble sizes displayed a strong peak in the 1 – 3 µm range with a precipitous drop-off
toward higher sizes (Figure 9).
The extended ‘tail’ in Figure 9 is most likely due to the increased efficiency of vaporization
for larger droplets – amplifying their presence proportionately. However, the presence of
bubbles generally larger than those in the original agitated microbubbles requires further
discussion. It was noticed that in several samples, especially those from higher lipid
concentrations, some vaporizable droplets were present as large as 1–2 µm (< 1.5%), and on
occasion could be observed as high as 3 – 4 µm. This indicates that the upper sizes shown in
Figure 7 most likely represent droplet sizes rather than bubbles remaining in the sample
(which were rarely, if ever, observed). By ideal gas law estimations, these droplets should
result in bubbles on the order of 10 – 25 µm (see Table 1), explaining the presence of the
larger vaporization-produced bubbles. These micron-sized droplets may be formed by larger
microbubbles present after agitation, as the particle sizer does detect some bubbles as large
as 25 – 30 µm in diameter, however, that bubbles larger than 15 µm typically comprise less
than 0.09% of the overall population suggests that there may be other mechanisms at work.
Because the samples were tested at high concentrations, it is possible that bubble fusion
could result from the vaporization of droplets in very close proximity. If this were occurring,
it would also have the effect of generally increasing the mode and mean bubble size
compared to the original bubble population. It is also possible that the higher dissolved gas
content of the samples due to room-air pressurization could lead to an increase in measured
bubble size, although some of the dissolved gas would diffuse through the porous
microcellulose tube into the degassed water bath before reaching the optical focus. This
could be mediated in future studies by pressurization with low boiling-point, low solubility
gasses. Alternately, secondary effects may be occurring during the condensation process. A
brief experiment was performed to explore the interplay of pressure and temperature on
microbubble condensation.
Influence of Secondary Effects on Microbubble Condensation
Agitated bubble samples were exposed to; a) cold only, or; b) pressurization with room-air
only to determine effects on the bubble population (Figure 10). Results show that when
exposed to reduced temperatures only, the bubble population did not change significantly.
When exposed to pressure only, the bubble population begins shifting toward the sub-
micron range (as shown previously), however, bubbles in the 20 – 30 µm size range begin to
appear in higher proportion. This suggests that some degree of secondary effects – such as
Ostwald ripening or bubble fusion – may be present during the pressurization process, which
requires further investigation. These results also seem to show that pressure is the main
driving force in the condensation procedure. Future studies will assess the resultant
microbubble size as a function of the rate and degree of pressurization in order to ascertain
whether these larger bubbles formed can be eliminated by refining of the process. In
addition to secondary effects that result in the presence of larger bubbles, the effect that
increased ambient pressure may have on causing a degree of microbubble dissolution prior
to condensation will need to be studied further to optimize the technique.
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Direct comparison of the two methods employed is not appropriate in light of the different
lipid and buffer formulations used. In the extrusion process, the aqueous solution was
prepared in a way to lower the freezing point significantly in order to operate at
temperatures where the bulk DFB solution would stay in the liquid phase. For the
microbubble condensation method, the aqueous solution was prepared primarily to produce
desired microbubble population characteristics. In these preliminary tests, the microbubble
condensation method appeared to be a much simpler approach that could produce DFB
droplets in large quantities. Although it is possible that an extrusion-based approach could
be optimized in formulation and technique to produce comparable results, the low surface
tension of perfluorocarbons and the high viscosity of the aqueous phase at the lower
temperatures used present a significant challenge.
Conclusion
These preliminary results demonstrate that pressurization and temperature-induced
condensation of pre-formed microbubbles may be both an effective and advantageous means
of producing contrast agents for ADV applications compared to conventional extrusion and
emulsion-based methods for some PFCs. The extent to which the method can be applied to
PFCs of higher boiling points will require further investigation. The samples formed by
microbubble condensation produced a high number of viable nanodroplets that could be
vaporized at clinically feasible pressures, resulting in a distribution of contrast-providing
microbubbles resembling the original microbubble sample. This method also may have
advantages with regard to commercialization of ADV technology, as nanodroplets can be
formed easily by adding a simple technique after traditional microbubble preparation.
These results highlight only two lipid formulations that can be used. Other lipid
formulations should make this technology amenable to not only ultrasound imaging, but
drug and gene delivery and therapy as well. The incorporation of 16:0 TAP in the lipid
formulation used for microbubble condensation, which helped minimize aggregation and
coalescence, is currently being pursued in our laboratories as a means of plasmid/gene
delivery. In addition, the low concentrations of lipids (0.75 – 3.0 mg/mL) utilized to
stabilize the DFB droplets makes these formulations more amenable to human use while
also minimizing the possibility of toxicity or bioeffects.
This study represents our initial efforts to develop an extravascular ultrasound contrast agent
based upon vaporizable nanodroplet technology. Results have demonstrated that ADV of
submicron sized droplets can be induced in vitro with pressures available to clinical
diagnostic ultrasound machines. Successful development of this exciting new agent may
complement current efforts for developing tissue selective ultrasound contrast agents for
both molecular imaging and therapy. Additional studies are ongoing to assess the level of
stability, extent of extravasation, and selective tissue targeting of these agents.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Estimations based on the Antoine equation demonstrate that DFB is a promising compound
for developing metastable nanoparticles due to its low vaporization energy for particles in
the 100 – 750 nm range compared to other PFCs typically studied as phase-change contrast
agents. Curves that rise above body temperature indicate potential for the encapsulated PFC
droplets to remain stable for the specified sizes due to the increased surface tension effects.
Calculations were performed using atmospheric pressure and a surface tension of 51 mN/m
for all compounds. This surface tension value was chosen based on lipid formulations
previously used by our group, and because it is near the upper limits that have been reported
in the literature24,25 for lipid or polymer encapsulation.
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DFB droplets with diameters in the low micron range were seen to vaporize as an inverse
function of initial diameter (N = 15). Droplets near the optical resolution limit of the
experimental setup could be vaporized with brief 2 µs pulses at mechanical indices well-
below the current clinical limit of 1.9 for diagnostic ultrasound imaging.
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Micron-sized DFB droplets produced by membrane extrusion were stable at 37°C and could
be subsequently vaporized by ultrasonic energy. The extrusion method produced a highly
varying size distribution of viable droplets, including (a) droplets near the optical resolution
of the system, and (b) some larger than 10 µm in diameter. The resulting increase in size
after vaporization was close to that predicted by ideal gas laws (approximately 5 to 6 times
the original droplet diameter).
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Representative bubble populations prior to microbubble condensation. Mean bubble size for
each lipid in order of increasing lipid concentration was 1.03 µm, 1.01 µm, and 1.20 µm,
while mode bubble size was 0.93 µm for all three. Concentrations in particles/mL were
4.8×109, 3.1×109, and 9.9×109, respectively.
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Example of sub-micron particle sizing of nanodroplets produced by the microbubble
condensation method. Peak sizes of 200–300 nm resulted which appeared to be independent
of lipid concentration. Mean droplet size for each curve in order of increasing lipid
concentration was 229 ± 120 nm, 345 ± 97 nm, and 325 ± 268 nm, respectively, while mode
droplet size was 220 nm, 295 nm, and 255 nm.
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Lipid control solution sub-micron sizing. A peak at 105 nm with a low count rate was
detected for the 3 mg/mL lipid solution, which did not appear in droplet samples at the same
lipid concentration.
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Condensation of original microbubble samples shows a shift of mode size into the sub-
micron range, as captured by an Accusizer 780A. For each lipid concentration, the resulting
mode size (0.64 µm, 0.57 µm, and 0.54 µm in order of increasing concentration) was near
the lower sensitivity of the machine (0.54 µm), indicating the sample is likely better
represented by the results of the sub-micron particle sizing (Figure 6). The data corresponds
well with measured resultant microbubble size after ADV as shown in Table 1.
Concentrations in particles/mL were 1.2×107, 2.4×107, and 8.4×107, respectively.
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Mid-plane droplet vaporization revealed microbubble sizes occurring predominantly in the 1
–3 µm range, with an increasing number of bubbles produced as lipid concentration
increased. Vaporization was induced with a 10 cycle pulse at 5 MHz with a mechanical
index of 1.7. Left: 0.75 mg/mL lipid concentration. Right: 3.0 mg/mL lipid concentration.
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Resulting bubble diameter as a function of increasing acoustic pressure for samples
originating from 3 mg/mL lipid solutions measured from bubbles collected at the top of the
microcellulose tube. Sizing profiles resemble original microbubble sizing profiles, indicating
successful generation and vaporization of condensed microbubbles. Mechanical indices of
1.2 and 1.7 result in similar bubble distributions, however, it is noted the higher pressure
produces a greater proportion of bubbles in the 1 – 2 µm range.
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Agitated microbubbles (3 mg/mL lipid concentration) exposed to room-air pressure only
show transition of mode size into the sub-micron range, although the presence of bubbles in
the 20–30 micron size range increases in proportion, suggesting secondary effects may be
occurring to some degree. Concentrations in particles/mL for the control bubbles and
pressurized sample were 4.8×109 and 2.5×108, respectively.
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